Skip to content
FearGreedChartHEALTH

Deals

Mergers and acquisitions

Merger deals signed or completed by US-listed drug, biotech and diagnostics companies over the past 90 days, from their SEC filings.

Recent deals

Newest first

Why deals matter

The pharma giants face patent expiries on drugs worth roughly $200 billion a year in sales by 2030. Their own labs don’t produce enough new medicines to replace that, so they buy biotech companies.

How much they pay says how they value biotech. A high premium over the market price means buyers think biotech shares are worth more than they trade for. A small premium means buyers see little gap between price and value.

What is counted

We search the full text of every 8-K filing with the SEC for a merger agreement, and keep filings from drug, biotech and diagnostics companies (SEC industry codes 2833 to 2836 and 8731) that report either:

  • Signing a deal: Item 1.01, entry into a material definitive agreement.
  • Completing a deal: Item 2.01, completion of an acquisition.

Each company is counted once per 90 days for each kind. Both sides of a deal often file, so one merger can count twice. Filings that only attach or mention an old merger agreement are left out. Deal values and premiums are not read from the filings.